Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1174-1180

  Kim, D Y ^a   Lee, J H ^a   Kim, S H ^a   Lim, S N ^a   Kim, S D ^a   Choi, Y ^a   Lee, Y S ^a   Kang, Y A ^a   Kang, S I ^a   Seol, M ^a   Ryu, S G ^a   Lee, K H ^a  

^a Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; SURVIVAL RATE; TREATMENT DURATION; CHRONIC DISEASE; CLASSIFICATION; EVALUATION STUDY; GRAFT VS HOST DISEASE; MORTALITY; PRACTICE GUIDELINE; SEVERITY OF ILLNESS INDEX; STANDARDS; UNITED STATES;

CHRONIC DISEASE; CLASSIFICATION; GRAFT VS HOST DISEASE; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; UNITED STATES;

EID: 77955013291     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.320     Document Type: Article

References (24)

1. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
2. Sutherland HJ, Fyles GM, Adams G, Hao Y, Lipton JH, Minden MD et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 1997; 19: 1129-1136.
3. Duell T, van Lint MT, Ljungman P, Tichelli A, Socie G, Apperley JF et al. Health and functional status of long-term survivors of bone marrow transplantation EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997; 126: 184-192.
4. Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 1993; 11: 319-327.
5. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS et al. Predictors of death from chronic graftversus- host disease after bone marrow transplantation. Blood 1989; 74: 1428-1435.
6. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facili- tated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14 (9 Suppl): 8-15.
7. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
8. Symons HJ, Fuchs EJ. Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant 2008; 42: 365-377.
9. Chen YB, Spitzer TR. Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia 2008; 22: 31-41.
10. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 674-682. (Pubitemid 36097807)
11. Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998; 22: 755-761.
12. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
13. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
14. Hashino S, Imamura M, Kasai M, Higa T, Naohara T, Sakamaki S et al. Bone marrow transplantation for hematological diseases in Hokkaido-June 1985 to December 1991. Jpn J Clin Oncol 1993; 23: 166-172.
15. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107: 409-418.
16. Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
17. Greinix HT, Nachbaur D, Krieger O, Eibl M, Knobl P, Kalhs P et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117: 914-923.
18. Akpek G. Clinical grading in chronic graft-versus-host disease: is it time for change? Leuk Lymphoma 2002; 43: 1211-1220.
19. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
20. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H et al. Incidence and outcome of chronic graftversus- host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007; 13: 1207-1215.
21. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S et al. Feasibility of NIH consensus criteria for chronic graft-versushost disease. Leukemia 2009; 23: 78-84.
22. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219-1226. (Pubitemid 32183742)
23. Lee JH, Lee JH, Choi SJ, Kim S, Seol M, Lee YS et al. Graftversus- host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. Br J Haematol 2003; 122: 637-644.
24. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.